Literature DB >> 20649476

Derivation of Huntington's disease-affected human embryonic stem cell lines.

Cara K Bradley1, Heather A Scott, Omar Chami, Teija T Peura, Biljana Dumevska, Uli Schmidt, Tomas Stojanov.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by an expansion of cytosine-adenine-guanine (CAG) repeats in the Huntingtin gene Htt. To facilitate research into HD, we have derived 4 human embryonic stem cell (hESC) lines containing ≥ 40 CAG repeats in exon 1 of Htt: SIVF017-HD (CAG₄₀), SIVF018-HD (CAG₄₆), SIVF020-HD (CAG₄₈), and SIVF046-HD (CAG₄₅). Additionally, we have derived a normal sibling-matched control for SIVF020-HD, cell line SIVF019. All 5 hESC lines had a normal karyotype, expressed pluripotency markers including Oct4, SSEA3, and Tra-1-81, and could be maintained in culture for multiple (>40) passages. Teratoma studies revealed that the hESC lines were capable of differentiating into cells representative of the 3 germ layers. Furthermore, in vitro neuronal differentiation experiments have confirmed that the hESC lines were able to generate MAP2-positive neuronal cells that express the Htt protein. Combined, these experiments confirm that the cell lines represent pluripotent stem cell lines. These HD-affected hESC lines will be made available to biomedical research laboratories and will provide a valuable tool to investigate the mechanisms and potential treatments for HD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20649476     DOI: 10.1089/scd.2010.0120

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  28 in total

1.  Vitrified blastocysts from Preimplantation Genetic Diagnosis (PGD) as a source for human Embryonic Stem Cell (hESC) derivation.

Authors:  Begoña Aran; Miquel Sole; Ignasi Rodriguez-Pizà; Mònica Parriego; Yolanda Muñoz; Montserrat Boada; Pere N Barri; Juan Carlos Izpisúa; Anna Veiga
Journal:  J Assist Reprod Genet       Date:  2012-06-27       Impact factor: 3.412

Review 2.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

3.  Female sex bias in human embryonic stem cell lines.

Authors:  Dalit Ben-Yosef; Ami Amit; Mira Malcov; Tsvia Frumkin; Ahmi Ben-Yehudah; Ido Eldar; Nava Mey-Raz; Foad Azem; Gheona Altarescu; Paul Renbaum; Rachel Beeri; Irit Varshaver; Talia Eldar-Geva; Silvina Epsztejn-Litman; Ephrat Levy-Lahad; Rachel Eiges
Journal:  Stem Cells Dev       Date:  2011-06-24       Impact factor: 3.272

4.  Human ESC-Derived Chimeric Mouse Models of Huntington's Disease Reveal Cell-Intrinsic Defects in Glial Progenitor Cell Differentiation.

Authors:  Mikhail Osipovitch; Andrea Asenjo Martinez; John N Mariani; Adam Cornwell; Simrat Dhaliwal; Lisa Zou; Devin Chandler-Militello; Su Wang; Xiaojie Li; Sarah-Jehanne Benraiss; Robert Agate; Andrea Lampp; Abdellatif Benraiss; Martha S Windrem; Steven A Goldman
Journal:  Cell Stem Cell       Date:  2018-12-13       Impact factor: 24.633

5.  Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.

Authors:  Bryan Zeitler; Steven Froelich; Kimberly Marlen; David A Shivak; Qi Yu; Davis Li; Jocelynn R Pearl; Jeffrey C Miller; Lei Zhang; David E Paschon; Sarah J Hinkley; Irina Ankoudinova; Stephen Lam; Dmitry Guschin; Lexi Kopan; Jennifer M Cherone; Hoang-Oanh B Nguyen; Guijuan Qiao; Yasaman Ataei; Matthew C Mendel; Rainier Amora; Richard Surosky; Josee Laganiere; B Joseph Vu; Anand Narayanan; Yalda Sedaghat; Karsten Tillack; Christina Thiede; Annette Gärtner; Seung Kwak; Jonathan Bard; Ladislav Mrzljak; Larry Park; Taneli Heikkinen; Kimmo K Lehtimäki; Marie M Svedberg; Jenny Häggkvist; Lenke Tari; Miklós Tóth; Andrea Varrone; Christer Halldin; Andrea E Kudwa; Sylvie Ramboz; Michelle Day; Jyothisri Kondapalli; D James Surmeier; Fyodor D Urnov; Philip D Gregory; Edward J Rebar; Ignacio Muñoz-Sanjuán; H Steve Zhang
Journal:  Nat Med       Date:  2019-07-01       Impact factor: 53.440

Review 6.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

Review 7.  Bioreactor engineering of stem cell environments.

Authors:  Nina Tandon; Darja Marolt; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Biotechnol Adv       Date:  2013-03-24       Impact factor: 14.227

Review 8.  Modelling human disease with pluripotent stem cells.

Authors:  Richard Siller; Sebastian Greenhough; In-Hyun Park; Gareth J Sullivan
Journal:  Curr Gene Ther       Date:  2013-04       Impact factor: 4.391

Review 9.  Pluripotent stem cells models for Huntington's disease: prospects and challenges.

Authors:  Richard L Carter; Anthony W S Chan
Journal:  J Genet Genomics       Date:  2012-05-09       Impact factor: 4.275

10.  Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.

Authors: 
Journal:  Cell Stem Cell       Date:  2012-06-28       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.